SCHEMBL2511792

SCHEMBL2511792

COC(=O)c1cc(S(C)(=O)=O)cc(Cl)c1N

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.45
ALDH1A1 P00352 9/20 0.45
NQO2 P16083 2/20 0.45
TSHR P16473 1/20 0.45
HPGD P15428 5/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 1/20 0.44
ABL1 P00519 1/20 0.44
LMNA P02545 1/20 0.44
KDM4E B2RXH2 8/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GLA P06280 3/20 0.43
POLB P06746 2/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ESR2 Q92731 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2517260 0.82 LMNA (0.60) GAAALDH1A1TSHRHPGDMAPT
SCHEMBL140598 0.78 KDM4E (0.61) GAAALDH1A1NQO2HPGDHSD17B10
SCHEMBL2872060 0.78 LMNA (0.68) GAAALDH1A1TSHRMAPTLMNA
SCHEMBL1258694 0.78 LMNA (0.54) GAAALDH1A1TSHRHSD17B10MAPT
SCHEMBL7414215 0.78 KDM4E (0.45) GAAALDH1A1TSHRHPGDHSD17B10
SCHEMBL1449764 0.77 CA1 (0.64) ALDH1A1LMNAPOLBCA1CA2
SCHEMBL6119775 0.77 GAA (0.50) GAAALDH1A1NQO2TSHRHPGD
SCHEMBL24792656 0.76 GAA (0.49) GAAALDH1A1NQO2TSHRHPGD
SCHEMBL3574538 0.76 GAA (0.49) GAAALDH1A1NQO2TSHRHPGD
SCHEMBL8355025 0.75 ALDH1A1 (0.42) GAAALDH1A1TSHRHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034822-B2 Glucokinase activators TAKEDA SAN DIEGO, INC. (US) 2011-10-11 US disclosed
US-8034822-B2 Glucokinase activators TAKEDA SAN DIEGO, INC. (US) 2011-10-11 US disclosed
EP-2001875-A2 GLUCOKINASE ACTIVATORS Takeda San Diego, Inc. (US) 2008-12-17 EP disclosed
WO-2007104034-A2 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. (US) 2007-09-13 WO disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 US disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 US disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213349-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GAA 56/4885ALDH1A1 1149/4885NQO2 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.